Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study
Clinical Breast Cancer · 2025-02 · 25 (2) · 164-171
DOI: 10.1016/j.clbc.2024.11.006 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Breast Cancer, 2025-02. Verfasst von Yoonwon Kook und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Institute for Breast Cancer Preci…. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: For patients who achieve pathologic complete response (pCR) after neoadjuvant chemotherapy with trastuzumab (T) and pertuzumab (P), the benefit of adding P to T remains uncertain. We compared survival outcomes according to the type of adjuvant anti-HER2 therapy in patients with pCR after chemotherapy with TP. METHOD: Patients who achieved pCR in both the breast and axilla after neoadjuvant chemotherapy with TP were included. Recurrence-free survival (RFS) and distant recurrence-free survival (DRFS) were evaluated. Univariate and multivariate Cox proportional hazards analyses were used to assess the impact of different adjuvant therapies on RFS and DRFS. RESULTS: In total, 386 patients were included, with 69 (17.9%) receiving adjuvant TP and 317 (82.1%) receiving adjuvant T alone. At a median follow-up of 49 months, the 3-year RFS rate was 96.1%. There was no significant difference in the 3-year RFS between groups (94.2% in TP and 95.6% in T), with an adjusted hazard ratio (HR) of 1.15 (95% CI, 0.37-3.55, P = .806). In the clinical node-positive group (n = 294), there was no difference in survival between groups (HR 1.64, 95% CI, 0.58-4.65, P = .35). The multivariate analysis showed no significant predictors of recurrence or distant recurrence, including clinical tumor size, nodal status, ER/PR/HER2 status, and adjuvant radiotherapy receipt. Among 11 patients with brain metastasis after pCR, there was no difference according to the type of adjuvant anti-HER2 therapy. CONCLUSIONS: In patients with pCR who responded to chemotherapy and dual HER2 blockade (TP), the 3-year RFS and brain metastasis-free survival did not differ according to the type of adjuvant anti-HER2 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Institute for Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul, Republic…
- Institute for Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei Universi…
- Division of Breast Surgery, Department of Surgery, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Republic of Korea.
- Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: sheol1981@hanmail.net.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kook, Y., Kim, J. H., Jang, J. S., Bae, S. J., Baek, S. H., Jeong, J., Choi, J. Y., Shin, D. S., Ryu, J. M., & Ahn, S. G. (2025). Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study. Clinical Breast Cancer, 25(2), 164-171. https://doi.org/10.1016/j.clbc.2024.11.006
Vancouver
Kook Y, Kim JH, Jang JS, Bae SJ, Baek SH, Jeong J, et al. Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study. Clinical Breast Cancer. 2025;25(2):164-171. doi:10.1016/j.clbc.2024.11.006
BibTeX
@article{Kook2025,
author = {Kook, Yoonwon and Kim, Jee Hung and Jang, Ji Soo and Bae, Soong June and Baek, Seung Ho and Jeong, Joon and Choi, Joon Young and Shin, Dong Seung and Ryu, Jai Min and Ahn, Sung Gwe},
title = {Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study},
journal = {Clinical Breast Cancer},
year = {2025},
volume = {25},
number = {2},
pages = {164--171},
doi = {10.1016/j.clbc.2024.11.006}
}
EUVIMED